TABLE 2.
Clinical characteristics of SOT recipients at the time of first-positive SARS-CoV-2 PCR test according to vaccination status at time of infection
| All SOT recipients, n = 143 | Unvaccinated, n = 33 (23.1%) | Vaccinated, n = 110 (76.9%) | p-value | |
| Age at time of first-positive SARS-CoV-2 PCR test, median (IQR) | 49 (40–59) | 46 (31–60) | 50 (42–58) | 0.369 |
| Sex (male), n (%) | 91 (63.6%) | 17 (51.5%) | 74 (67.3%) | 0.149 |
| Time from transplantation to first-positive SARS-CoV-2 PCR test in years, median (IQR) | 6.0 (2.5–10.0) | 5.0 (2.0–10.0) | 6.0 (3.0–9.8) | 0.751 |
| Transplant type, n (%) | ||||
| Kidney | 105 (73.4%) | 26 (78.8%) | 79 (71.8%) | 0.569 |
| Liver | 38 (26.6%) | 7 (21.2%) | 31 (28.2%) | |
| Comorbidities, n (%) | ||||
| Cardiovascular disease | 95 (66.4%) | 23 (69.7%) | 72 (65.5%) | 0.808 |
| Chronic pulmonary disease | 17 (11.9%) | 5 (15.2%) | 12 (10.9%) | 0.543 |
| Diabetes mellitus | 32 (22.4%) | 6 (18.2%) | 26 (23.6%) | 0.674 |
| Immunosuppressive treatment at time of first-positive SARS-CoV-2 PCR test, n (%) | ||||
| No antimetabolites | 13 (9.1%) | 2 (6.1%) | 11 (10.0%) | 0.593 |
| Mycophenolate | 121 (84.6%) | 28 (84.8%) | 93 (84.5%) | |
| Azathioprine | 9 (6.3%) | 3 (9.1%) | 6 (5.5%) | |
| Calcineurin inhibitor (Ciclosporin, Tacrolimus) | 135 (94.4%) | 31 (93.9%) | 104 (94.5%) | 1.00 |
| mTOR inhibitor (Sirolimus, Everolimus) | 4 (2.8%) | 2 (6.1%) | 2 (1.8%) | 0.228 |
| Corticosteroids | 122 (85.3%) | 29 (87.9%) | 93 (84.5%) | 0.783 |
| Number of vaccine doses at time of first-positive SARS-CoV-2 PCR test, n (%) | ||||
| 0 | 29 (20.3%) | 29 (87.9%) | 0 (0%) | <0.001 |
| 1 | 4 (2.8%) | 4 (12.1%) | 0 (0%) | |
| 2 | 46 (32.2%) | 0 (0%) | 46 (41.8%) | |
| 3 | 64 (44.8%) | 0 (0%) | 64 (58.2%) | |
| SARS-CoV-2 varianta, n (%) | ||||
| Wild-type | 8 (11.3%) | 8 (61.5%) | 0 (0.0%) | <0.001 |
| Alpha | 7 (9.9%) | 2 (15.4%) | 5 (8.6%) | |
| Delta | 51 (71.8%) | 3 (23.1%) | 48 (82.8%) | |
| Omicron | 5 (7.0%) | 0 (0.0%) | 5 (8.6%) | |
| Outpatient monoclonal antibody treatment with Sotrovimab | 37 (28.0%) | 2 (6.1%) | 35 (31.8%) | 0.003 |
| Outpatient monoclonal antibody treatment with Regn-Cov2 | 3 (2.7%) | 0 (0%) | 3 (2.7%) | 1.00 |
Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory coronavirus 2.
a
Missing data from 72 infections (20 unvaccinated and 52 vaccinated).